Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
126.6 USD | -2.93% | +2.99% | +0.45% |
Sales 2024 * | 444M 483M | Sales 2025 * | 727M 791M | Capitalization | 6.89B 7.5B |
---|---|---|---|---|---|
Net income 2024 * | -281M -306M | Net income 2025 * | 8M 8.7M | EV / Sales 2024 * | 16.8 x |
Net Debt 2024 * | 570M 620M | Net Debt 2025 * | 277M 301M | EV / Sales 2025 * | 9.85 x |
P/E ratio 2024 * |
-24.8
x | P/E ratio 2025 * |
2,483
x | Employees | 879 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 10.3% |
Latest transcript on Ascendis Pharma A/S
1 day | +0.75% | ||
1 week | +7.71% | ||
Current month | -5.80% | ||
1 month | -4.04% | ||
3 months | -16.05% | ||
6 months | +42.66% | ||
Current year | +3.54% |
Managers | Title | Age | Since |
---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Scott Smith
DFI | Director of Finance/CFO | 50 | 16-08-07 |
Stina Singel
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Albert Cha
CHM | Chairman | 51 | 14-10-31 |
General Counsel | 53 | 07-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 11 M€ | -6.03% | - | |
0.48% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 126.5 | -2.98% | 62 920 |
24-05-24 | 130.4 | +0.75% | 250,225 |
24-05-23 | 129.4 | -1.30% | 405,348 |
24-05-22 | 131.1 | +6.75% | 1,393,999 |
24-05-21 | 122.8 | +1.47% | 682,413 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.54% | 7.48B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.46% | 22.1B | |
-8.58% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ASND Stock